-
Promising advances are being made on the microbicide front: U.S. funding appears imminent for microbicide research and development, a new corporate partnership has been struck with an international research group to step up testing of antiviral AIDS gels, and a number of potential candidates are moving through the research pipeline.
-
What is the policy for providing emergency contraception (EC) at your facility? About 81% of respondents to the 2004 Contraceptive Technology Update Contraception Survey say their facilities prescribe EC on site and provide emergency contraceptive pills (ECPs) at any time, which continues a trend of strong support for the method.
-
Should a woman who is obese and continues to gain weight on Depo-Provera [depot medroxyprogesterone acetate (DMPA), Pfizer, New York City] be allowed to continue its use if she so desires? Are providers contributing to the health risk of obesity by allowing a woman to do so?
-
Post hoc analysis of 3 large multicenter trials of patients with acute coronary syndromes demonstrates a strong association between transfusion and mortality.
-
This multicenter prospective observational study reveals that transfusion practice in the critically ill has not changed in the past decade. 44% of ICU patients receive transfusions, and transfusions continue to be associated with worse clinical outcomes.
-
The Infection Risk of Acid-Suppressing Drugs; Is Rosuvastatin As Safe As Other Statins?; Which Estrogen Preparation is the Safest?; FDA Actions.
-
-
-
Brain natriuretic peptide (bnp), also called b-type natriuretic peptide, is mainly secreted by the cardiac ventricles during increased ventricular wall stress. BNP plasma concentration provides important information on the prognosis in patients with heart failure, myocardial infarction, and acute coronary syndromes without ST-segment elevation.
-
In September, health officials had concerns about the severity of the upcoming influenza season. Then Chiron Corp. notified the Centers for Disease Control and Prevention (CDC) in Atlanta on Oct. 5 that it would not provide its influenza vaccine (Fluvirin) for the year because of contamination issues. This essentially cut the nations trivalent inactivated vaccine supply in half.
